Brokers Issue Forecasts for SOPHiA GENETICS Q2 Earnings

SOPHiA GENETICS SA (NASDAQ:SOPH) – Stock analysts at HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for SOPHiA GENETICS in a research report issued to clients and investors on Monday, July 20th. HC Wainwright analyst S. Ramakanth forecasts that the company will earn ($0.15) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. HC Wainwright also issued estimates for SOPHiA GENETICS’s Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.58) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.01) EPS, FY2027 earnings at ($0.20) EPS, FY2028 earnings at $0.04 EPS, FY2029 earnings at $0.34 EPS and FY2030 earnings at $0.69 EPS.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday. BTIG Research restated a “buy” rating and issued a $8.00 price objective on shares of SOPHiA GENETICS in a report on Monday, June 15th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $9.00.

SOPHiA GENETICS Stock Up 2.7%

Shares of NASDAQ SOPH opened at $6.50 on Wednesday. The firm has a fifty day simple moving average of $5.30 and a two-hundred day simple moving average of $5.05. SOPHiA GENETICS has a 12 month low of $2.92 and a 12 month high of $6.74. The company has a current ratio of 2.06, a quick ratio of 1.90 and a debt-to-equity ratio of 1.05. The firm has a market capitalization of $545.28 million, a PE ratio of -12.50 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The company had revenue of $21.69 million during the quarter, compared to the consensus estimate of $20.40 million. SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%.

Insiders Place Their Bets

In other SOPHiA GENETICS news, CTO Abhimanyu Verma sold 6,944 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $5.51, for a total transaction of $38,261.44. Following the completion of the transaction, the chief technology officer owned 197,456 shares of the company’s stock, valued at approximately $1,087,982.56. This trade represents a 3.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Zhenyu Xu sold 7,393 shares of the business’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $5.17, for a total transaction of $38,221.81. Following the sale, the insider owned 614,887 shares in the company, valued at approximately $3,178,965.79. This trade represents a 1.19% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 176,711 shares of company stock valued at $959,913 in the last 90 days. Corporate insiders own 4.88% of the company’s stock.

Institutional Investors Weigh In On SOPHiA GENETICS

Several hedge funds have recently bought and sold shares of the business. Hennion & Walsh Asset Management Inc. purchased a new stake in SOPHiA GENETICS in the second quarter worth about $567,000. Royal Bank of Canada lifted its holdings in shares of SOPHiA GENETICS by 3,130.2% during the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock valued at $96,000 after purchasing an additional 18,781 shares during the last quarter. Sei Investments Co. purchased a new position in shares of SOPHiA GENETICS during the first quarter valued at approximately $1,772,000. Principal Financial Group Inc. boosted its position in shares of SOPHiA GENETICS by 0.7% in the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after purchasing an additional 9,800 shares in the last quarter. Finally, Hodges Capital Management Inc. bought a new stake in shares of SOPHiA GENETICS in the 1st quarter worth approximately $2,157,000. Institutional investors own 31.59% of the company’s stock.

Trending Headlines about SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: HC Wainwright initiated coverage on SOPHiA GENETICS SA with a Buy rating and $12 price target, signaling strong upside potential versus the current trading level. Street Insider analyst coverage article
• Positive Sentiment: HC Wainwright’s longer-term estimates call for SOPHiA GENETICS to move from losses to profitability by FY2028 and stronger earnings in FY2029-FY2030, which could reinforce a growth narrative for the stock.
• Neutral Sentiment: The company said it will report second-quarter 2026 results on August 4, which is a key near-term catalyst but does not by itself change fundamentals. PR Newswire earnings date announcement
• Neutral Sentiment: Management also highlighted AI-driven precision medicine in a recent media appearance, which may support the company’s growth story but is not a direct financial update. MSN interview article
• Negative Sentiment: HC Wainwright’s near-term EPS estimates remain negative through FY2027, suggesting SOPHiA GENETICS is still expected to burn cash before reaching profitability.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.